In order to kill cancer cells and sabotage CD47-SIRPa (CD47-signal regulatory protein alpha) connections, the hybrid cell membrane nanovesicles, or hNVs, can interface with circulating tumour cells (CTCs) in vascular lumens and accumulate at the site of resection (48). The gene discussed is SIRPA; the disease is cancer.